How are CYP2D6 and Stress related?

The direct relationship between CYP2D6 and stress is not well established. CYP2D6 is a key drug-metabolizing enzyme involved in the breakdown of many antidepressants (e.g., SSRIs, tricyclics) and beta-blockers used for stress-related conditions. Genetic variants in CYP2D6 classify individuals as poor, intermediate, extensive, or ultrarapid metabolizers, which can affect drug efficacy and side effects. Stress may modulate CYP2D6 activity via cortisol and other stress hormones, but evidence is limited to small human studies and animal models, with inconsistent results. Direct associations between CYP2D6 polymorphisms and subjective stress perception or stress biomarkers (e.g., cortisol) are not robustly replicated. Importantly, DTC pharmacogenetic tests for CYP2D6 often lack clinical context, ignoring drug interactions, liver function, and other medications, which can lead to unsafe dosing recommendations. Therefore, while CYP2D6 is relevant for pharmacotherapy of stress-related disorders, it is not a direct 'stress gene' marker. The evidence is mechanistic and indirect, with no strong human outcome data linking CYP2D6 variants to stress resilience or vulnerability.